DMTK Stock Price, DermTech Inc Quote, Chart

Market Summary

USD0.59+0.01

Market Closed

1.72%

DMTK Stock Price

View Fullscreen

DMTK RSI Chart

DMTK Valuation

Market Cap

20.4M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

1.34

Price/Free Cashflow

-0.26

DMTK Price/Sales (Trailing)

DMTK Profitability

Operating Margin

1.80%

Return on Equity

-176.45%

Return on Assets

-82.74%

Free Cashflow Yield

-381.25%

DMTK Fundamentals

DMTK Revenue

Revenue (TTM)

15.3M

Rev. Growth (Yr)

31.06%

Rev. Growth (Qtr)

0.23%

DMTK Earnings

Earnings (TTM)

-100.9M

Earnings Growth (Yr)

32.36%

Earnings Growth (Qtr)

0.38%

Breaking Down DMTK Revenue

Last 7 days

-7.8%

Last 30 days

-16.9%

Last 90 days

-54.3%

Trailing 12 Months

-81.3%

How does DMTK drawdown profile look like?

DMTK Financial Health

Current Ratio

4.59

DMTK Investor Care

Shares Dilution (1Y)

14.02%

Diluted EPS (TTM)

-3.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.3M	14.0M	14.4M	15.3M
2022	13.0M	14.1M	14.7M	14.5M
2021	6.9M	9.1M	10.8M	11.8M
2020	4.3M	4.6M	5.4M	5.9M
2019	2.5M	2.5M	2.4M	3.4M
2018	1.2M	1.6M	2.0M	2.4M
2017	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of DermTech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	sun kevin m	sold (taxes)	-311	0.7	-445	chief financial officer
Mar 05, 2024	akhavan ramin	sold (taxes)	-3,297	0.88	-3,747	general counsel
Mar 05, 2024	sun kevin m	sold (taxes)	-4,354	0.88	-4,948	chief financial officer
Jan 05, 2024	akhavan ramin	sold (taxes)	-4,803	1.5	-3,202	general counsel
Dec 11, 2023	sun kevin m	sold	-648	1.45	-447	chief financial officer
Dec 11, 2023	ibarra claudia	sold	-479	1.45	-331	chief operating officer
Dec 08, 2023	ibarra claudia	sold	-3,675	1.41	-2,607	chief operating officer
Dec 07, 2023	akhavan ramin	sold	-5,765	1.53	-3,768	general counsel
Dec 07, 2023	ibarra claudia	sold	-5,983	1.53	-3,911	chief operating officer
Dec 07, 2023	sun kevin m	sold	-7,617	1.53	-4,979	chief financial officer

Which funds bought or sold DMTK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-38.15	-17,000	5,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-13.00	-85,651	45,913	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-105	70.00	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-524	351	-%
Apr 24, 2024	PSI Advisors, LLC	sold off	-100	-1,225	-	-%
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	-1,048	702	-%
Apr 23, 2024	United Asset Strategies, Inc.	reduced	-0.74	-18,648	12,338	-%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	sold off	-100	-1,000	-	-%
Apr 18, 2024	STATE OF MICHIGAN RETIREMENT SYSTEM	sold off	-100	-105,000	-	-%
Apr 18, 2024	WOODMONT INVESTMENT COUNSEL LLC	unchanged	-	-88,275	59,131	-%

Are Funds Buying or Selling DMTK?

Are funds buying DMTK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DMTK

No. of Funds

Unveiling DermTech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 08, 2024	van herk investments b.v.	4.8%	1,628,057	SC 13G/A
Dec 12, 2023	rtw investments, lp	0%	0	SC 13D/A
Jun 16, 2023	van herk investments b.v.	5.0%	1,559,931	SC 13G/A
Feb 14, 2023	casdin capital, llc	0%	0	SC 13G/A
Feb 03, 2023	state street corp	0.45%	137,349	SC 13G/A
Nov 08, 2022	rtw investments, lp	9.99%	3,018,666	SC 13D/A
Jul 11, 2022	state street corp	0.57%	170,866	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	484,692	SC 13G
Feb 14, 2022	casdin capital, llc	5.87%	1,745,000	SC 13G/A
Feb 11, 2022	state street corp	9.58%	2,845,483	SC 13G

Recent SEC filings of DermTech Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	SC 13G	Major Ownership Report
Apr 26, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Mar 12, 2024	4/A	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 07, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to DermTech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.5B	23.7B	-0.93%	6.50%	41.46	7.69	-8.94%	-35.72%
IDXX	41.5B	3.7B	-7.44%	3.05%	49.1	11.33	8.72%	24.44%
A	40.3B	6.7B	-6.59%	3.31%	32.64	5.99	-2.81%	-6.58%
DGX	14.9B	9.3B	2.40%	-4.82%	17.61	1.6	-3.29%	6.68%
MEDP	12.3B	2.0B	-1.91%	100.24%	39.22	6.24	25.57%	21.62%
CRL	11.8B	4.1B	-15.01%	24.62%	24.77	2.85	3.86%	-2.39%
NTRA	11.1B	1.1B	1.32%	82.46%	-25.45	10.22	31.99%	20.63%
EXAS	10.7B	2.5B	-11.98%	-7.20%	-52.35	4.28	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-21.41%	-29.07%	1.7K	2.83	28.93%	111.61%
GH	2.1B	563.9M	-3.40%	-19.97%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	390.9M	280.3M	-28.23%	-2.96%	-2.05	1.39	-12.89%	-148.37%
ACRS	84.4M	31.2M	-5.56%	-86.21%	-0.95	2.7	5.03%	-1.81%
APDN	74.2M	9.0M	918.60%	338.04%	-10.27	8.25	-53.31%	2.21%
AWH	41.1M	9.2M	-2.92%	-32.04%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

DermTech Inc News

Latest updates

DermTech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.2%	3,924	3,915	3,980	3,477	2,994	3,573	4,233	3,718	3,165	3,030	3,119	2,524	2,122	1,362	844	1,557	1,589	565	614	596	629
Cost Of Revenue	-6.9%	3,484	3,743	3,972	3,821	3,350	3,694	3,273	3,554	3,040	2,898	2,624	2,002	1,725	1,608	1,445	1,203	1,204	779	686	635	-
Gross Profit	155.8%	440	172	8.00	-344	-356	-121	960	164	125	132	495	522	397	-246	-601	354	385	-214	-72.00	-39.00	-
Operating Expenses	1.1%	20,192	19,982	32,140	31,701	28,523	29,140	30,794	30,355	26,484	20,451	17,802	13,935	9,861	9,151	8,826	7,355	5,500	5,945	3,256	2,964	331
S&GA Expenses	3.7%	8,422	8,123	13,033	15,417	13,598	14,632	15,001	15,443	13,330	9,826	7,907	6,512	5,105	4,594	3,433	2,944	2,431	1,976	1,032	864	-
R&D Expenses	-6.9%	3,348	3,595	3,887	4,409	5,097	5,702	6,915	6,338	5,990	4,426	3,594	2,251	1,914	1,618	864	897	650	757	518	572	-
Interest Expenses	-50.0%	1.00	2.00	1.00	1.00	3.00	3.00	4.00	3.00	4.00	5.00	4.00	4.00	-	-	-	-	-	-	-	-	-
Net Income	0.4%	-19,091	-19,164	-31,363	-31,270	-28,223	-28,772	-29,580	-30,108	-26,053	-20,112	-17,102	-15,068	-10,702	-9,281	-9,597	-6,897	-5,556	-5,726	-3,692	-5,156	504
Net Income Margin	13.9%	-6.60*	-7.66*	-8.53*	-8.25*	-8.04*	-7.80*	-7.48*	-7.17*	-6.62*	-5.83*	-5.71*	-6.52*	-	-	-	-	-	-	-	-	-
Free Cashflow	34.3%	-12,544	-19,092	-23,460	-22,785	-23,163	-24,813	-25,120	-25,469	-23,736	-16,619	-13,743	-10,728	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.6%	122	138	157	177	202	194	216	240	248	270	276	265	70.00	57.00	65.00	72.00	18.00	24.00	12.00	12.00	80.00
Current Assets	-18.7%	62.00	76.00	94.00	112	136	161	184	208	233	254	272	262	67.00	55.00	62.00	70.00	17.00	24.00	0.00	0.00	5.00
Cash Equivalents	-1.3%	37.00	37.00	43.00	48.00	78.00	95.00	120	145	177	204	230	219	24.00	15.00	61.00	68.00	15.00	21.00	0.00	0.00	5.00
Inventory	-16.1%	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	0.00
Net PPE	-11.1%	5.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	0.00	-	-	0.00
Liabilities	-0.1%	65.00	65.00	69.00	70.00	70.00	39.00	38.00	36.00	19.00	18.00	8.00	8.00	8.00	5.00	6.00	6.00	6.00	5.00	7.00	7.00	11.00
Current Liabilities	6.4%	13.00	13.00	16.00	16.00	16.00	17.00	15.00	14.00	12.00	11.00	8.00	7.00	5.00	4.00	-	-	6.00	5.00	2.00	2.00	11.00
Shareholder's Equity	-21.7%	57.00	73.00	88.00	107	132	155	179	203	230	252	267	257	62.00	52.00	58.00	66.00	12.00	19.00	5.00	5.00	5.00
Retained Earnings	-4.7%	-423	-404	-385	-354	-323	-294	-266	-236	-206	-180	-160	-143	-128	-117	-108	-98.45	-91.55	-86.00	2.00	2.00	-71.38
Additional Paid-In Capital	0.7%	481	478	474	462	456	451	445	441	436	432	428	400	190	169	166	165	103	105	-	-	66.00
Shares Outstanding	0.8%	35.00	34.00	33.00	31.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	85.00	-	-	-	147	-	-	-	978	-	-	-	151	-	-	-	6.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	33.3%	-12,707	-19,043	-23,201	-22,028	-21,230	-24,801	-24,406	-24,823	-22,680	-15,899	-12,811	-10,716	-6,747	-8,157	-6,383	-7,397	-6,080	-7,715	-25.70	-2,706	-829
Share Based Compensation	-0.4%	3,151	3,163	7,515	4,736	5,267	4,936	4,837	3,894	3,830	3,736	3,538	2,172	1,449	1,373	1,125	1,022	104	685	257	258	-
Cashflow From Investing	-4.0%	12,243	12,757	13,058	-8,194	3,539	-466	141	-7,533	-4,523	-7,596	-178	-215	-2,857	-37,282	-1,026	-175	-157	-41.00	-6.00	-6.00	-
Cashflow From Financing	-103.3%	-24.00	726	4,461	916	-33.00	433	-10.00	527	25.00	971	24,003	205,278	19,227	-1,038	589	60,120	174	25,807	11.00	-136,914	2,610

DMTK Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 15,296	$ 14,518
Cost of revenues:
Cost of revenues:	15,020	13,871
Gross profit	276	647
Operating expenses:
Sales and marketing	44,995	58,674
Research and development	15,239	24,052
General and administrative	43,781	36,086
Total operating expenses	104,015	118,812
Loss from operations	(103,739)	(118,165)
Other income:
Interest income, net	2,846	1,341
Change in fair value of warrant liability	5	141
Total other income	2,851	1,482
Net loss	$ (100,888)	$ (116,683)
Weighted average shares outstanding used in computing net loss per share, basic (in shares)	32,641,376	30,038,959
Weighted average shares outstanding used in computing net loss per share, diluted (in shares)	32,641,376	30,038,959
Net loss per share of common stock outstanding, basic (in dollars per share)	$ (3.09)	$ (3.88)
Net loss per share of common stock outstanding, diluted (in dollars per share)	$ (3.09)	$ (3.88)
Test revenue
Revenues:
Total revenues	$ 14,384	$ 13,790
Cost of revenues:
Cost of revenues:	14,792	13,702
Contract revenue
Revenues:
Total revenues	912	728
Cost of revenues:
Cost of revenues:	$ 228	$ 169

DMTK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 36,741	$ 77,757
Short-term marketable securities	19,123	48,411
Accounts receivable	2,584	4,172
Inventory	1,004	1,757
Prepaid expenses and other current assets	2,300	3,940
Total current assets	61,752	136,037
Property and equipment, net	4,988	6,375
Operating lease right-of-use assets	51,722	56,007
Restricted cash	3,468	3,488
Other assets	0	168
Total assets	121,930	202,075
Current liabilities:
Accounts payable	1,484	2,419
Accrued compensation	6,664	7,894
Accrued liabilities	2,017	3,464
Short-term deferred revenue	196	109
Current portion of operating lease liabilities	3,069	1,634
Current portion of finance lease obligations	17	116
Total current liabilities	13,447	15,636
Warrant liability	0	5
Long-term finance lease obligations, less current portion	38	53
Operating lease liabilities, long-term	51,270	54,028
Total liabilities	64,755	69,722
Stockholders’ equity:
Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 34,524,677 and 30,297,408 shares issued and outstanding at December 31, 2023 and 2022, respectively	3	3
Additional paid-in capital	480,929	456,171
Accumulated other comprehensive income/(loss)	178	(774)
Accumulated deficit	(423,935)	(323,047)
Total stockholders’ equity	57,175	132,353
Total liabilities and stockholders’ equity	$ 121,930	$ 202,075

About DermTech Inc

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

CEO	Mr. Bret Christensen
WEBSITE	dermtech.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	278

DermTech Inc Frequently Asked Questions

What is the ticker symbol for DermTech Inc? What does DMTK stand for in stocks?

DMTK is the stock ticker symbol of DermTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DermTech Inc (DMTK)?

As of Fri Apr 26 2024, market cap of DermTech Inc is 20.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DMTK stock?

You can check DMTK's fair value in chart for subscribers.

What is the fair value of DMTK stock?

You can check DMTK's fair value in chart for subscribers. The fair value of DermTech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DermTech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DMTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DermTech Inc a good stock to buy?

The fair value guage provides a quick view whether DMTK is over valued or under valued. Whether DermTech Inc is cheap or expensive depends on the assumptions which impact DermTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMTK.

What is DermTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, DMTK's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMTK PE ratio will change depending on the future growth rate expectations of investors.